
Asceniv Market Report 2026
Epidemiology, Pipeline Analysis, Market Insights & Forecasts
Asceniv Market Overview
• The Asceniv market growth in the historic period has been driven by established efficacy of ivig therapies, rising awareness of primary immunodeficiency • Market expansion is supported by increasing pid diagnosis rates, shift toward home infusion models • Growth Driver: Impact Of Rising Respiratory Diseases On Market Growth • Market Trend: Product Innovations In Asceniv Storage Boost Accessibility And Usability • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.What Is Covered Under Asceniv Market?
Asceniv refers to an immunoglobulin (human) injection used to strengthen the immune system by providing antibodies to help protect against infections. It is primarily indicated for individuals with primary humoral immunodeficiency (PI), a condition where the body struggles to produce sufficient antibodies, making them more susceptible to infections. The main types of indications in asceniv are primary humoral immunodeficiency and other indications. Primary humoral immunodeficiency refers to a group of rare genetic disorders where the immune system's ability to produce antibodies is impaired. It is formulated in liquid form and lyophilized form, catering to various end users, including hospitals, clinics, and home care.
What Is The Asceniv Market Size and Share 2026?
The growth in the historic period can be attributed to established efficacy of ivig therapies, rising awareness of primary immunodeficiency, hospital adoption of immunoglobulin infusions, clinical success in infection reduction, availability of plasma derived antibodies.What Is The Asceniv Market Growth Forecast?
The growth in the forecast period can be attributed to increasing pid diagnosis rates, shift toward home infusion models, improved plasma supply management, expansion of specialty immunology services, rising long term therapy compliance. Major trends in the forecast period include rising use of immunoglobulin replacement therapies, growing diagnosis of primary immunodeficiency disorders, expansion of long term antibody infusion treatments, increasing adoption of home based immunotherapy, improved infection prevention in immunocompromised patients.Global Asceniv Market Segmentation
1) By Indication: Primary Humoral Immunodeficiency, Other Indications 2) By Formulation: Liquid Form, Lyophilized Form 3) By End User: Hospitals, Clinics, HomecareWhat Are The Drivers Of The Asceniv Market?
The increasing prevalence of respiratory diseases is expected to propel the growth of the asceniv market going forward. Respiratory diseases refer to conditions that affect the lungs and airways, ranging from infections like pneumonia to chronic conditions like asthma and COPD. The rise in respiratory diseases is driven by factors such as air pollution, smoking, and climate change, along with aging populations and increased exposure to infections. Asceniv treats respiratory diseases by enhancing the immune system with antibodies, aiding individuals with immune deficiencies or viral respiratory conditions in fighting infections. For instance, in December 2023, according to the National Institutes of Health, a US-based government agency, the number of COPD cases was expected to rise by 112 million, reaching a total of 592 million by 2050, which would represent 9.5% of the eligible population. Therefore, the increasing prevalence of respiratory diseases is driving the growth of the Asceniv industry. Increasing prevalence of immunodeficiency diseases is expected to propel the growth of the asceniv market going forward. Immunodeficiency diseases refer to conditions where the immune system's ability to fight infections and diseases is compromised or entirely absent. The rising prevalence of immunodeficiency diseases is driven by improved diagnostic methods, leading to better detection, and the aging population. ASCENIV helps immunodeficiency disease patients by providing a concentrated and effective intravenous immunoglobulin therapy that enhances immune function, reduces susceptibility to infections, and supports overall immune system health, improving their quality of life. For instance, in October 2024, according to the UK Health Security Agency, a UK-based government agency, there were 6,008 HIV diagnoses in England (including individuals previously diagnosed abroad) in 2023, marking a 51% rise from 3,975 cases reported in 2022. Therefore, increasing prevalence of immunodeficiency diseases is driving the growth of the Asceniv industry.Key Players In The Global Asceniv Market
Major companies operating in the asceniv market are ADMA Biologics Inc.Global Asceniv Market Trends and Insights
Major companies operating in the asceniv market are focusing on developing product innovations, such as extended room temperature storage conditions for Asceniv, to enhance its stability, improve accessibility, and reduce storage and transportation challenges. Extended room temperature storage conditions for Asceniv refer to the ability to store the product at room temperature for a prolonged period without compromising its efficacy or safety. For instance, in March 2024, ADMA Biologics, a US-based biotechnology company, received FDA approval for extended room temperature storage conditions for its intravenous immunoglobulin products, ASCENIV and BIVIGAM. Both products can now be stored at room temperature (25°C) for up to four weeks during their 36-month shelf life, improving usability and distribution. This change facilitates better inventory management and enhances access for healthcare providers, especially in areas with limited refrigeration. ASCENIV is indicated for treating primary humoral immunodeficiency in adults and adolescents, while BIVIGAM is used for various forms of this condition.Regional Insights
North America was the largest region in the asceniv market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.What Defines the Asceniv Market?
The asceniv market consists of sales of products including Gamunex-C, Privigen, Gammagard, Flebogamma, and Octagam. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.What Key Data and Analysis Are Included in the Asceniv Market Report 2026?
The asceniv market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the asceniv industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Asceniv Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $ billion |
| Revenue Forecast In 2035 | $ billion |
| Growth Rate | No CAGR found from 2026 to 2035 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 - 2035 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2035 |
| Segments Covered | Indication, Formulation, End User |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, ... |
| Key Companies Profiled | ADMA Biologics Inc. |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |
